07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Glycosphingolipid storage disorders Adenosine A2A receptor (ADORA2A) In vitro studies suggest ADORA2A agonists could help treat Niemann-Pick disease type C1...
07:00 , Aug 8, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Ischemia/reperfusion injury Adenosine A2B receptor (ADORA2B) Patient sample and mouse studies suggest agonizing ADORA2B could help prevent ischemia and reperfusion injury during liver transplant....
07:00 , Aug 30, 2012 |  BC Innovations  |  Cover Story

Dissociating the effects of A2A agonism

The vasodilatory effects of adenosine A2A receptor agonists make them useful as cardiac stress agents in imaging but have made it difficult to exploit these molecules' potent anti-inflammatory effects. 1 Researchers in Germany have dissociated...
07:00 , Jun 21, 2012 |  BC Innovations  |  Targets & Mechanisms

ADORAble implants

Researchers at the New York University Langone Medical Center have found a way to ward off a leading cause of joint implant failure. 1 The group has shown that adenosine A2A receptor agonists can block...
07:00 , Mar 26, 2012 |  BC Week In Review  |  Clinical News

BVT: Completed Phase II enrollment

CRO Ergomed completed enrollment of 120 patients in a Phase II trial evaluating oral BVT.115959. CBT Development, a virtual company between venture investors Avlar BioVentures and Excalibur Fund Managers, partnered with Ergomed last year to...
07:00 , May 23, 2011 |  BC Week In Review  |  Company News

Ergomed Group deal

CBT Development Ltd. , a virtual company between venture investors Avlar BioVentures Ltd. (Cambridge, U.K.) and Excalibur Fund Managers Ltd. (Cambridge, U.K.), and CRO Ergomed partnered to co-develop CBT's neuropathic pain candidate BVT.115959 . The...
08:00 , Nov 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Pain Adenosine A2A receptor (ADORA2A) Studies in rats suggest that agonizing ADORA2A could help treat neuropathic pain. In rats, an ADORA2A agonist reduced allodynia and...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Company News

Biovitrum, Proximagen deal

The companies signed a letter of intent for Biovitrum to sell its Cambridge Biotechnology Ltd. subsidiary to Proximagen in exchange for an undisclosed percentage of future revenues generated by the subsidiary. Cambridge's pipeline includes a...
08:00 , Jan 26, 2009 |  BC Week In Review  |  Company News

Biovitrum hematology, endocrine, neurology news

Biovitrum markets products for hemophilia, chemotherapy-induced nausea and vomiting (CINV), chemotherapy-induced oral mucositis and rheumatoid arthritis (RA). Last year, the company discontinued its early stage small molecule research and reduced headcount by 100 (20%) to...
01:48 , Jan 23, 2009 |  BC Extra  |  Company News

Biovitrum to spin out R&D subsidiary

Biovitrum (SSE:BVT) plans to spin out its U.K. R&D subsidiary, Cambridge Biotechnology. Cambridge's pipeline of small molecules includes BVT.115959 , an adenosine A2A receptor agonist in Phase II testing to treat neuropathic pain; undisclosed Phase...